Abdel-Rahman O, et al. - Researchers used Alberta Cancer Registry and other provincial electronic medical registries (2004 to 2018) to study patterns of adjuvant chemotherapy in patients with resected rectal adenocarcinomas after neoadjuvant chemoradiation and surgical resection. This analysis included 532 patients who met eligibility criteria: 347 patients were treated with adjuvant fluoropyrimidine-only chemotherapy and 185 patients underwent adjuvant oxaliplatin-based chemotherapy. Older age, higher Charlson comorbidity index, and no involved lymph nodes in the surgical pathology were the variables that were related to use of fluoropyrimidine-only adjuvant chemotherapy. According to findings of this real-world study, no improved survival outcomes were achieved with oxaliplatin-based adjuvant chemotherapy when compared with fluoropyrimidine-only chemotherapy.